DOCSLIB.ORG

Induction of a TRAIL Mediated Suicide Program by Interferon Alpha in Primary E€Usion Lymphoma

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Induction of a TRAIL Mediated Suicide Program by Interferon Alpha in Primary E€Usion Lymphoma Oncogene (2001) 20, 7029 ± 7040 ã 2001 Nature Publishing Group All rights reserved 0950 ± 9232/01 $15.00 www.nature.com/onc Induction of a TRAIL mediated suicide program by interferon alpha in primary eusion lymphoma Ngoc L Toomey1,4, Vadim V Deyev2,4, Charles Wood3, Lawrence H Boise2, Duncan Scott1, Lei Hua Liu1, Lisa Cabral1, Eckhard R Podack2, Glen N Barber2 and William J Harrington Jr*,1 1Department of Medicine University of Miami School of Medicine, Miami, Florida, FL 33136, USA; 2Department of Microbiology and Immunology, University of Miami School of Medicine, Miami, Florida, FL 33136, USA; 3School of Biological Sciences, University of Nebraska, Lincoln, Nebraska, NE 68588, USA Gammaherpes viruses are often detected in lymphomas Virus (EBV) or Human Herpes Virus Type 8 (HHV-8) arising in immunocompromised patients. We have found have been isolated from lymphomas found in im- that Azidothymidine (AZT) alone induces apoptosis in munosuppressed organ transplant recipients, children Epstein Barr Virus (EBV) positive Burkitt's lymphoma with hereditary immunode®ciencies and patients with (BL) cells but requires interferon alpha (IFN-a) to induce acquired immunode®ciency (AIDS) (Swinnen, 1999; apoptosis in Human Herpes Virus Type 8 (HHV-8) Goldsby and Carroll, 1998; Knowles, 1999). Many of positive Primary Eusion Lymphomas (PEL). Our these tumors can be categorized into distinct subtypes analysis of a series of AIDS lymphomas revealed that based on a variety of morphologic and molecular IFN-a selectively induced very high levels of the Death criteria. For example, AIDS associated large cell Receptor (DR) tumor necrosis factor-related apoptosis- diuse or immunoblastic lymphomas (DLCL, IBL) inducing ligand (TRAIL) in HHV-8 positive PEL lines are often EBV positive while AIDS associated Burkitt's and primary tumor cells whereas little or no induction lymphomas (BL) less frequently contain EBV (Gaidano was observed in primary EBV+ AIDS lymphomas and et al., 1994). A recently de®ned subtype, AIDS related EBV7Burkitt's lines. AZT and IFN-a mediated HHV-8 associated Primary Eusion Lymphoma (PEL) apoptosis in PEL was blocked by stable overexpression (Nador et al., 1996), usually occurs in the setting of of dominant negative Fas Associated Death Domain severe immunode®ciency of advanced HIV infection. (FADD), decoy receptor 2 (DcR2), soluble TRAIL PELs dier from most AIDS lymphomas by their receptor fusion proteins (DR-4 and DR-5) and thymi- absence of a discernable primary tumor mass, infre- dine. Trimeric TRAIL (in place of IFN-a) similarly quent expression of B lymphocyte dierentiation synergized with AZT to induce apoptosis in HHV-8 antigens, and lack of c-myc gene rearrangement positive PEL cells. This is the ®rst demonstration that (Mullaney et al., 2000; Gaidano et al., 2000; Demario IFN-a induces functional TRAIL in a malignancy that and Liebowitz, 1998). In general, immunode®ciency can be exploited to eect a suicide program. This novel related herpesvirus associated lymphomas are aggres- antiviral approach to Primary Eusion lymphomas is sive and poorly responsive to conventional chemother- targeted and may represent a highly eective and apy (Swinnen, 2000; Levine, 2000). relatively non-toxic therapy. Oncogene (2001) 20, Although AZT was originally developed as an anti- 7029 ± 7040. cancer agent, this thymidine nucleoside analog has demonstrated relatively little activity in solid tumors Keywords: human Herpes Virus Type 8; Epstein Barr (Findenig et al., 1996). Interest in AZT was revived virus; TRAIL; apoptosis; lymphoma; FADD only when it was found to inhibit HIV reverse transcriptase (De Clercq, 1992). To exert this antiviral activity, AZT must be phosphorylated by cellular Introduction thymidine kinase (TK) (Arner et al., 1992). Our initial studies indicated that there were two distinctly dierent Gammaherpes viruses are frequently associated with pro-apoptotic eects of AZT and Interferon alpha lymphoproliferative disease in immunocompromised (IFN-a) in primary lymphoma cell lines derived from individuals (Okano and Gross, 2000). Epstein-Barr AIDS patients. EBV+ BL cells underwent apoptosis in the presence of AZT alone while HHV-8+ PELs required the addition of IFN-a to undergo signi®cant *Correspondence: WJ Harrington Jr, University of Miami School of programmed cell death (Lee et al., 1999). Medicine/Sylvester Comprehensive Cancer Center, Room 3400 (D8- Interferons have multiple activities involved in host 4), 1475 NW 12th Avenue, Miami, Florida, FL 33136, USA; defense including anti-proliferative and antiviral eects. E-mail: [email protected] It is known that the interferons, which are potently 4These authors contributed equally to this work Received 14 May 2001; revised 17 July 2001; accepted 2 August upregulated by viruses and double stranded RNA 2001 (dsRNA), can synthesize eectors of apoptosis such as Interferon induces TRAIL in primary effusion lymphoma NL Toomey et al 7030 2'5' oligoadenylate synthetase (2' ±5'A) which activates These data demonstrate that IFN-a upregulates RNAseL and degrades viral mRNA (Player and TRAIL in Primary Eusion Lymphomas while AZT Torrence, 1998). Interferon also induces synthesis of sensitizes these cells to TRAIL mediated apoptosis dsRNA activated protein kinase (PKR), which phos- resulting in the activation of a suicide program in phorylates the translation initiator eIF-2-a and inhibits this cancer. The unique tumorcidal eect of AZT protein synthesis in the cell (Zamanian-Daryoush et al., and IFN-a may have important applications for 2000). Recently, interferons were also found to induce therapy of herpesvirus associated lymphoproliferative expression of the pro-apoptotic protein tumor necrosis disease. factor-related apoptosis-inducing ligand (TRAIL) in human dendritic cells and T lymphocytes which is capable of inducing apoptosis in TRAIL receptor Results expressing targets (Fanger et al., 1999; Grith et al., 1999; Balachandran et al., 2000). AZT and IFN-a act synergistically to induce apoptosis in IFN also potentiates the adaptive immune response HHV-8+ PEL cells through upregulation of major histocompatibility complexes (MHC) and activation of cytotoxic T cells We have demonstrated that AZT and IFN-a have (CTLs) and natural killer cells (NKs) (Mingari et al., clinical activity against malignant herpesvirus asso- 2000). CTLs can recognize and kill cells that present ciated lymphomas (Lee et al., 1999). To further foreign peptides, in association with MHC, through the investigate the apoptotic eects, we studied the perforin/granzyme pathway (Barry et al., 2000). HHV-8+ PEL lines, BC-3 and BCBL-1, as well as Another important mechanism of immune eector the EBV+ AIDS BL primary lines, BL-7 and BL-5. clearance of virally infected or cancerous cells is by All lines were cultured for 48 h in the presence of transmission of an apoptotic signal through ligand medium, AZT (10 mg/ml) or IFN-a (1000 u/ml) binding to members of the tumor necrosis (TNF) alone, or AZT and IFN-a together. As shown in family of receptors (Peter et al., 1997). The binding of Figure 1a, AZT alone induced marked apoptosis in ligands such as Fas-L or TRAIL to extracellular the EBV+Burkitt's lymphoma lines (BL-7, BL-5) receptor domains (APO-1 (Fas/CD95), DR-5) results while IFN-a did not induce apoptosis nor add to in recruitment of components of the death domain the cytopathic eect of AZT. In contrast, HHV-8+ containing the adaptor molecule Fas associated death PEL cells (BC-3, BCBL-1) only underwent marked domain (FADD) and subsequent activation of FLICE apoptosis in the presence of both AZT and IFN-a (caspase 8) by autoproteolysis. Following recruitment (Figure 1a). Similar experiments revealed that other and cleavage of procaspase 8, downstream caspases are HHV-8+ PEL lines, BC-1 and BC-5, also required activated, including caspase 3, resulting in apoptosis. both AZT and IFN-a to undergo signi®cant TRAIL mediated signaling and apoptosis is blocked apoptosis (data not shown). Therefore, a general upon its binding to decoy receptors (DcR1, DcR2) property of HHV-8+ PEL cells was that AZT and which do not recruit FADD (Walczak and Krammer, IFN-a induced substantial apoptosis together but not 2000; Ashkenazi and Dixit, 1999; Bodmer et al., 2000). separately. This cytotoxic eect was seen only in The role of DR-4 in apoptosis is unclear since its virus infected lymphomas as both agents had no expression in FADD7/7 ®broblasts still results in cell eect on herpes virus negative BL cells (Ramos) death (Yeh et al., 1998). Signaling through other (Figure 1b). Further experiments on another herpes- members of the TNF receptor family also may activate virus negative lymphoma cell line (BJAB) demon- non-apoptotic processes such as in¯ammatory re- strated that AZT, with or without IFN-a, induced sponses and lymphoid organogenesis (Magnusson and little or no cytotoxic activity (data not shown). Vaux, 1999). To further investigate the mechanism of AZT and IFN-a induces TRAIL in PEL cells IFN-a mediated apoptosis, we studied a series of lymphoma cell lines and primary lymphoma cells It has recently been shown that IFN-a mediates the derived from AIDS patients. We report here that expression of several pro-apoptotic genes and can HHV-8+ PEL cell lines and primary tumor cells from induce cell death through a FADD dependent a PEL patient express high levels of TRAIL when mechanism (Balachandran et al., 2000). Since IFN-a cultured with IFN-a. Despite the induction of TRAIL potentiated apoptosis in PEL, we investigated its in PEL cells by IFN-a, apoptosis was only potentiated eect on the regulation of pro-apoptotic factors in upon the addition of AZT. In PEL cells, AZT and IFN-a sensitive and resistant B cell lymphomas. IFN-a mediated apoptosis was blocked by expression Accordingly, BC-3 and BL-7 cells were treated for of dominant negative FADD (FADD DN), decoy 8 h with AZT (10 mg/ml), IFN-a (1000 m/ml) or the receptor 2 (DcR2), soluble TRAIL receptor fusion chemotherapeutic agent etoposide (10 mg/ml).
Load more

Recommended publications
  • Porvac® Subunit Vaccine E2-CD154 Induces Remarkable Rapid Protection Against Classical Swine Fever Virus
    Article Porvac® Subunit Vaccine E2-CD154 Induces Remarkable Rapid Protection against Classical Swine Fever Virus Yusmel Sordo-Puga 1, Marisela Suárez-Pedroso 1 , Paula Naranjo-Valdéz 2, Danny Pérez-Pérez 1, Elaine Santana-Rodríguez 1, Talia Sardinas-Gonzalez 1, Mary Karla Mendez-Orta 1, Carlos A. Duarte-Cano 1, Mario Pablo Estrada-Garcia 1 and María Pilar Rodríguez-Moltó 1,* 1 Animal Biotechnology Department, Center for Genetic Engineering and Biotechnology, P.O. Box 6162, Havana 10600, Cuba; [email protected] (Y.S.-P.); [email protected] (M.S.-P.); [email protected] (D.P.-P.); [email protected] (E.S.-R.); [email protected] (T.S.-G.); [email protected] (M.K.M.O.); [email protected] (C.A.D.); [email protected] (M.P.E.) 2 Central Laboratory Unit for Animal Health (ULCSA), Havana 11400, Cuba; [email protected] * Correspondence: [email protected]; Tel.: +53-7-2504419 Abstract: Live attenuated C-strain classical swine fever vaccines provide early onset protection. These vaccines confer effective protection against the disease at 5–7 days post-vaccination. It was previously reported that intramuscular administration of the Porvac® vaccine protects against highly virulent Citation: Sordo-Puga, Y.; classical swine fever virus (CSFV) “Margarita” strain as early as seven days post-vaccination. In Suárez-Pedroso, M.; Naranjo-Valdéz, order to identify how rapidly protection against CSFV is conferred after a single dose of the Porvac® P.; Pérez-Pérez, D.; subunit vaccine E2-CD154, 15 swine, vaccinated with a single dose of Porvac®, were challenged Santana-Rodríguez, E.; 3 intranasally at five, three, and one day post-vaccination with 2 × 10 LD50 of the highly pathogenic Sardinas-Gonzalez, T.; Mendez-Orta, Cuban “Margarita” strain of the classical swine fever virus.
    [Show full text]
  • Age- and Gender-Specific Modulation of Serum Osteopontin and Interferon-Α by Osteopontin Genotype in Systemic Lupus Er
    Genes and Immunity (2009) 10, 487–494 & 2009 Macmillan Publishers Limited All rights reserved 1466-4879/09 $32.00 www.nature.com/gene ORIGINAL ARTICLE Age- and gender-specific modulation of serum osteopontin and interferon-a by osteopontin genotype in systemic lupus erythematosus SN Kariuki1, JG Moore1, KA Kirou2,MKCrow2, TO Utset1 and TB Niewold1 1Section of Rheumatology, University of Chicago, Chicago, IL, USA and 2Mary Kirkland Center for Lupus Research, Hospital for Special Surgery, New York, NY, USA Osteopontin (OPN) is a multifunctional cytokine involved in long bone remodeling and immune system signaling. Additionally, OPN is critical for interferon-a (IFN-a) production in murine plasmacytoid dendritic cells. We have previously shown that IFN-a is a heritable risk factor for systemic lupus erythematosus (SLE). Genetic variants of OPN have been associated with SLE susceptibility, and one study suggests that this association is particular to men. In this study, the 3 0 UTR SLE-risk variant of OPN (rs9138C) was associated with higher serum OPN and IFN-a in men (P ¼ 0.0062 and P ¼ 0.0087, respectively). In women, the association between rs9138 C and higher serum OPN and IFN-a was restricted to younger subjects, and risk allele carriers showed a strong age-related genetic effect of rs9138 genotype on both serum OPN and IFN-a (Po0.0001). In African- American subjects, the 5 0 region single nucleotide polymorphisms, rs11730582 and rs28357094, were associated with anti- RNP antibodies (odds ratio (OR) ¼ 2.9, P ¼ 0.0038 and OR ¼ 3.9, P ¼ 0.021, respectively). Thus, we demonstrate two distinct genetic influences of OPN on serum protein traits in SLE patients, which correspond to previously reported SLE-risk variants.
    [Show full text]
  • Interferon-Γ Enhances Interleukin 12 Production in Rheumatoid Synovial
    Interferon-γ Enhances Interleukin 12 Production in Rheumatoid Synovial Cells via CD40-CD154 Dependent and Independent Pathways MINETAKE KITAGAWA, HIROSHI SUZUKI, YOSHIHIRO ADACHI, HIROSHI NAKAMURA, SHINICHI YOSHINO, and TAKAYUKI SUMIDA ABSTRACT. Objective. To determine the role of interferon-γ (IFN-γ) in CD40-CD154 dependent production of interleukin 12 (IL-12) by synovial cells of patients with rheumatoid arthritis (RA). Methods. We examined the effects of IFN-γ, tumor necrosis factor-α (TNF-α), and granulocyte- macrophage colony stimulating factor (GM-CSF) on CD40 expression on CD68+ synovial macrophage-lineage cells (SMC). The effects of IFN-γ and soluble CD154 (sCD154) on IL-12 production by RA synovial cells were determined by ELISA. Results. CD68+ SMC expressed substantial levels of CD40. IFN-γ, but not TNF-α or GM-CSF, markedly upregulated CD40 expression on CD68+ SMC. IFN-γ also dose dependently increased IL- γ 12 production by synovial cells. The effects of IFN- on CD40 expression (EC50 = 127.4 U/ml) were observed at a concentration 19 times lower than the effects on IL-12 production (EC50 = 6.8 U/ml). Treatment with IFN-γ at a concentration low enough to augment CD40 expression but not IL-12 production enhanced spontaneous IL-12 production synergy with sCD154. The synergistic enhance- ment of spontaneous IL-12 production was abrogated by CD40-Fc. In contrast, IL-12 production induced by high concentration of IFN-γ was not neutralized by CD40-Fc. Conclusion. IFN-γ enhanced IL-12 production via both CD40-CD154 dependent and independent pathways in RA synovium. IFN-γ may play a crucial role in the development of RA synovitis through regulation of IL-12 production.
    [Show full text]
  • Dysregulated Interferon Response Underlying Severe COVID-19
    viruses Review Dysregulated Interferon Response Underlying Severe COVID-19 LeAnn Lopez y, Peter C. Sang y, Yun Tian y and Yongming Sang * Department of Agricultural and Environmental Sciences, College of Agriculture, Tennessee State University, 3500 John A. Merritt Boulevard, Nashville, TN 37209, USA; [email protected] (L.L.); [email protected] (P.C.S.); [email protected] (Y.T.) * Correspondence: [email protected]; Tel.: +1-615-963-5183 These authors contributed equally. y Academic Editor: Andrew Davidson Received: 27 October 2020; Accepted: 9 December 2020; Published: 13 December 2020 Abstract: Innate immune interferons (IFNs), including type I and III IFNs, constitute critical antiviral mechanisms. Recent studies reveal that IFN dysregulation is key to determine COVID-19 pathogenesis. Effective IFN stimulation or prophylactic administration of IFNs at the early stage prior to severe COVID-19 may elicit an autonomous antiviral state, restrict the virus infection, and prevent COVID-19 progression. Inborn genetic flaws and autoreactive antibodies that block IFN response have been significantly associated with about 14% of patients with life-threatening COVID-19 pneumonia. In most severe COVID-19 patients without genetic errors in IFN-relevant gene loci, IFN dysregulation is progressively worsened and associated with the situation of pro-inflammation and immunopathy, which is prone to autoimmunity. In addition, the high correlation of severe COVID-19 with seniority, males, and individuals with pre-existing comorbidities will be plausibly explained by the coincidence of IFN aberrance in these situations. Collectively, current studies call for a better understanding of the IFN response regarding the spatiotemporal determination and subtype-specificity against SARS-CoV-2 infections, which are warranted to devise IFN-related prophylactics and therapies.
    [Show full text]
  • Pegasys, INN-Peginterferon Alfa-2A
    SCIENTIFIC DISCUSSION This module reflects the initial scientific discussion and scientific discussion on procedures, which have been finalised before 1 April 2005. For scientific information on procedures after this date please refer to module 8B. 1. Introduction Peginterferon alfa-2a is a polyethylene glycol (PEG)-modified form of human recombinant interferon alfa-2a intended for the treatment of adult patients with chronic hepatitis C (CHC) or chronic hepatitis B (CHB). Chronic hepatitis C is a major public health problem: hepatitis C virus (HCV) is responsible for a large proportion of chronic liver disease, accounting for 70% of cases of chronic hepatitis in industrialised countries. Globally there are an estimated 150 million chronic carriers of the virus, including 5 million in Western Europe. Without treatment approximately 30% of those infected with HCV will develop cirrhosis over a time frame of 30 years or more. For those with HCV-related cirrhosis, the prognosis is poor – a significant proportion will develop a life-threatening complication (either decompensated liver disease or an hepatocellular carcinoma) within a few years. The only therapy for those with advanced cirrhosis is liver transplantation, which carries a high mortality. In those who survive transplantation, viral recurrence in the new liver is almost inevitable and a significant proportion of infected liver grafts develop a progressive fibrosis that leads to recurrence of cirrhosis within 5 years. Interferon alfa monotherapy has been shown to be effective for the treatment of chronic hepatitis although sustained response rates occurred in approximately 15 to 30 % of patients treated for long duration (12-18 months). The current reference therapy is interferon alpha in combination with ribavirin, which resulted in an increase in biochemical and virological sustained response rates to approximately 40 % in naïve patients.
    [Show full text]
  • Induces Antigen Presentation in B Cells Cell-Activating Factor of The
    B Cell Maturation Antigen, the Receptor for a Proliferation-Inducing Ligand and B Cell-Activating Factor of the TNF Family, Induces Antigen Presentation in B Cells This information is current as of September 27, 2021. Min Yang, Hidenori Hase, Diana Legarda-Addison, Leena Varughese, Brian Seed and Adrian T. Ting J Immunol 2005; 175:2814-2824; ; doi: 10.4049/jimmunol.175.5.2814 http://www.jimmunol.org/content/175/5/2814 Downloaded from References This article cites 54 articles, 36 of which you can access for free at: http://www.jimmunol.org/content/175/5/2814.full#ref-list-1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication by guest on September 27, 2021 *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2005 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology B Cell Maturation Antigen, the Receptor for a Proliferation-Inducing Ligand and B Cell-Activating Factor of the TNF Family, Induces Antigen Presentation in B Cells1 Min Yang,* Hidenori Hase,* Diana Legarda-Addison,* Leena Varughese,* Brian Seed,† and Adrian T.
    [Show full text]
  • Interferon-Based Biopharmaceuticals: Overview on the Production, Purification, and Formulation
    Review Interferon-Based Biopharmaceuticals: Overview on the Production, Purification, and Formulation Leonor S. Castro 1,†, Guilherme S. Lobo 1,†, Patrícia Pereira 2 , Mara G. Freire 1 ,Márcia C. Neves 1,* and Augusto Q. Pedro 1,* 1 CICECO–Aveiro Institute of Materials, Chemistry Department, University of Aveiro, Campus Universitário de Santiago, 3810-193 Aveiro, Portugal; [email protected] (L.S.C.); [email protected] (G.S.L.); [email protected] (M.G.F.) 2 Centre for Mechanical Engineering, Materials and Processes, Department of Chemical Engineering, University of Coimbra, Rua Sílvio Lima-Polo II, 3030-790 Coimbra, Portugal; [email protected] * Correspondence: [email protected] (M.C.N.); [email protected] (A.Q.P.) † These authors contributed equally to this work. Abstract: The advent of biopharmaceuticals in modern medicine brought enormous benefits to the treatment of numerous human diseases and improved the well-being of many people worldwide. First introduced in the market in the early 1980s, the number of approved biopharmaceutical products has been steadily increasing, with therapeutic proteins, antibodies, and their derivatives accounting for most of the generated revenues. The success of pharmaceutical biotechnology is closely linked with remarkable developments in DNA recombinant technology, which has enabled the production of proteins with high specificity. Among promising biopharmaceuticals are interferons, first described by Isaacs and Lindenmann in 1957 and approved for clinical use in humans nearly thirty years later. Interferons are secreted autocrine and paracrine proteins, which by regulating several biochemical Citation: Castro, L.S.; Lobo, G.S.; pathways have a spectrum of clinical effectiveness against viral infections, malignant diseases, Pereira, P.; Freire, M.G.; Neves, M.C.; and multiple sclerosis.
    [Show full text]
  • Pegasys®) Peginterferon Alfa-2B (Peg-Intron®
    Peginterferon alfa-2a (Pegasys®) Peginterferon alfa-2b (Peg-Intron®) UTILIZATION MANAGEMENT CRITERIA DRUG CLASS: Pegylated Interferons BRAND (generic) NAME: Pegasys (peginterferon alfa-2a) Single-use vial 180 mcg/1.0 mL; Prefilled syringe 180 mcg/0.5 mL Peg-Intron (peginterferon alfa-2b) Single-use vial (with 1.25 mL diluent) and REDIPEN®: 50 mcg, 80 mcg, 120 mcg, 150 mcg per 0.5 mL. FDA-APPROVED INDICATIONS PEG-Intron (peginterferon alfa-2b): Combination therapy with ribavirin: • Chronic Hepatitis C (CHC) in patients 3 years of age and older with compensated liver disease. • Patients with the following characteristics are less likely to benefit from re-treatment after failing a course of therapy: previous nonresponse, previous pegylated interferon treatment, significant bridging fibrosis or cirrhosis, and genotype 1 infection. Monotherapy: CHC in patients (18 years of age and older) with compensated liver disease previously untreated with interferon alpha. Pegasys (Peginterferon alfa-2a): • Treatment of Chronic Hepatitis C (CHC) in adults with compensated liver disease not previously treated with interferon alpha, in patients with histological evidence of cirrhosis and compensated liver disease, and in adults with CHC/HIV coinfection and CD4 count > 100 cells/mm3. o Combination therapy with ribavirin is recommended unless patient has contraindication to or significant intolerance to ribavirin. Pegasys monotherapy is indicated for: • Treatment of adult patients with HBeAg positive and HBeAg negative chronic hepatitis B who have compensated
    [Show full text]
  • Gut Microbiota and Regulation of Myokine-Adipokine Function
    Available online at www.sciencedirect.com ScienceDirect Gut microbiota and regulation of myokine-adipokine function 1 1 Francesco Suriano , Matthias Van Hul and Patrice D Cani Both skeletal muscle and adipose tissue are considered as particular interest on how they affect metabolic homeosta- endocrine organs due to their ability to produce and secrete sis of the whole body. several bioactive peptides (e.g. myokines and adipokines). Those bioactive molecules are well known for their capacity to Myokines influence whole-body homeostasis and alterations in their In the body, there are different type of muscles (skeletal, production/secretion are contributing to the development of cardiac,smooth),whichperform different functions based on various metabolic disorders. While it is well accepted that their location. They are mainly responsible for maintaining changes in the composition and functionality of the gut and changing body posture, producing force and motion, microbiota are associated with the onset of several generating heat (both through shivering and non-shivering), pathological disorders (e.g. obesity, diabetes, and cancer), its as well as facilitating movement of internal organs, such as contribution to the regulation of the myokine-adipokine profile the heart, digestive organs, and blood vessels [2,3]. Skeletal and function remains largely unknown. This review will focus on muscle is the largest organ in the human body, accounting for myokines and adipokines with a special interest on their about 30% of body mass in women and 40% in men, though interaction with the gut microbiota. muscle mass is affected by several conditions such as fasting, physical inactivity, cancer, obesity, untreated diabetes, hor- Address monal changes, heart failure, AIDS, chronic obstructive UCLouvain, Universite´ catholique de Louvain, WELBIO - Walloon Excellence in Life Sciences and BIOtechnology, Louvain Drug Research pulmonary disease (COPD), or aging [4].
    [Show full text]
  • Innate and Adaptive Signals Enhance Differentiation and Expansion of Dual-Antibody Autoreactive B Cells in Lupus
    ARTICLE DOI: 10.1038/s41467-018-06293-z OPEN Innate and adaptive signals enhance differentiation and expansion of dual-antibody autoreactive B cells in lupus Allison Sang1, Thomas Danhorn 2, Jacob N. Peterson1, Andrew L. Rankin3,4, Brian P. O’Connor1,2,5,6, Sonia M. Leach2,5, Raul M. Torres1,5 & Roberta Pelanda1,5 1234567890():,; Autoreactive B cells have a major function in autoimmunity. A small subset of B cells expressing two distinct B-cell-antigen-receptors (B2R cells) is elevated in many patients with systematic lupus erythematosus (SLE) and in the MRL(/lpr) mouse model of lupus, and is often autoreactive. Here we show, using RNAseq and in vitro and in vivo analyses, signals that are required for promoting B2R cell numbers and effector function in autoimmune mice. Compared with conventional B cells, B2R cells are more responsive to Toll-like receptor 7/9 and type I/II interferon treatment, display higher levels of MHCII and co-receptors, and depend on IL-21 for their homeostasis; moreover they expand better upon T cell-dependent antigen stimulation, and mount a more robust memory response, which are characteristics essential for enhanced (auto)immune responses. Our findings thus provide insights on the stimuli for the expansion of an autoreactive B cell subset that may contribute to the etiology of SLE. 1 Department of Immunology and Microbiology, University of Colorado School of Medicine, Aurora, CO 80045, USA. 2 Center for Genes, Environment and Health, National Jewish Health, Denver, CO 80206, USA. 3 Inflammation and Immunology, Pfizer Research, Cambridge, MA 02140, USA. 4 Immuno- Oncology Discovery, FivePrime Therapeutics, South San Francisco, CA 94080, USA.
    [Show full text]
  • Introna, INN-Interferon Alfa-2B
    SCIENTIFIC DISCUSSION This module reflects the initial scientific discussion and scientific discussion on procedures, which have been finalised before 1 August 2003. For scientific information on procedures after this date please refer to module 8B. 1. Introduction This was a full application to obtain a single European Marketing Authorisation via the centralised procedure for interferon alfa-2b. National Marketing Authorisations exist in all Member States for the use of interferon alfa–2b (IntronA). IntronA is indicated in the treatment of Chronic Hepatitis B, Chronic Hepatitis C, Hairy Cell Leukemia, Chronic Myelogenous Leukemia, Multiple Myeloma, Follicular Lymphoma, Carcinoid tumor, Malignant Melanoma and AIDS-related Kaposi’s Sarcoma. The harmonization of the SPC for the listed indications was achieved in June 1997 through a referral under Article 11 of Council directive 75/319/EEC as amended. The new data filed with the centralised application concerned an extension of Chronic Hepatitis B approval in adults to children (1 to 17 years of age), the combination of interferon alfa-2b with ribavirin as first line treatment for patients with Chronic Hepatitis C and an update of the other indications including acknowledgement that cytarabine is commonly used with interferon alfa-2b in Chronic Myelogenous Leukemia. The indication AIDS-related Kaposi’s Sarcoma was deleted. The CPMP focused the evaluation on the new information provided in support of the centralised application. 2. Chemical, pharmaceutical and biologicals aspects The qualitative and quantitative composition of the medicinal product centrally authorised IntronA and of the nationally licensed IntronA, are strictly identical. The manufacturers and the manufacturing process are those already approved for the manufacture of the nationally authorized Intron-A.
    [Show full text]
  • Interferon-Á Sensitises Human Osteosarcoma Cells to Trail-Mediated Apoptosis
    CANCER GENOMICS & PROTEOMICS 1: 95-104 (2004) Interferon-Á Sensitises Human Osteosarcoma Cells to Trail-mediated Apoptosis IDUN M. MIKKELSEN1, CECILIE LØKKE1, TROND FLAGSTAD1,3 and ØYVIND S. BRULAND2,4 1Department of Paediatrics and 2Department of Oncology, Institute of Clinical Medicine, University of Tromsø, N-9037 Tromsø;. 3Department of Paediatrics, University Hospital of North Norway, N-9037 Tromsø; 4The Norwegian Radium Hospital, Montebello, Oslo, Norway Abstract. Background: Nearly half of all patients with efficiently induces cell death in osteosarcoma cell lines and osteosarcoma are still not cured by the currently employed should be further investigated as a potential future therapy. multimodal treatment. New strategies are therefore needed to further improve the outcome. Tumour necrosis factor-related Osteosarcoma (OS) is the most common primary malignant apoptosis-inducing ligand (TRAIL/Apo2) is able to induce tumour of the bone in children and adolescents and is programmed cell death in transformed cells, while normal characterised by its high propensity to metastasise to the cells remain unaffected. Materials and Methods: We have lungs and the skeleton (1,2). Currently, only half of the investigated the effect of TRAIL in combination with IFN-Á patients with OS are cured after multimodal therapy with on four human osteosarcoma cell lines; Saos-2, U2OS, surgery, high-dose combinatory chemotherapy and KPDXM and OHS, and on one normal human fibroblast cell irradiation (3,4). The acquisition of resistant phenotypes of line, MRC-5. Results: One of the four osteosarcoma cell lines OS is also a major problem during and after the use of was TRAIL-resistant, but was sensitised to TRAIL-mediated chemotherapy and radiation therapy (4-6).
    [Show full text]